Archived article
Please note that tax, investment, pension and ISA rules can change and the information and any views contained in this article may now be inaccurate.
Cancer treatment and vaccine delivery system developer N4 Pharma reported a full-year loss, owing to R&D and administrative costs.
Pre-tax losses for the year through December amounted to £0.94m, compared to losses of £1.39m on-year.
Chief executive Nigel Theobald said the company had made considerable progress in understanding how its Nuvec delivery system worked, putting it in a stronger position for potential collaboration discussions with licensing partners.
At 9:11am: (LON:N4P) N4 Pharma Plc Ord 0.4p share price was 0p at 3.15p